FOGPHARMA
Live / Registered — Registered (as of 19 Dec 2023)
What this means for you
Registered since 19 Dec 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88693697
- Registration number
- 7249597
- Mark type
- Stylized text
- Filed
- 15 Nov 2019
- Published for opposition
- 23 Jun 2020
- Registered
- 19 Dec 2023
- Attorney of record
- Steven A. Abreu
Goods and services
- Class 005 — Pharmaceuticals: House mark for pharmaceutical and medical preparations containing biomedical compounds, namely, peptides, stapled peptides, and synthetic peptides, all comprised of amino acids for the medical treatment of cancer, inflammatory conditions, immunological disorders, cardiovascular conditions, infectious diseases, and neurological conditions; biomedical compounds for medical purposes, namely, miniproteins and cell-penetrating miniproteins (CPMPs) arrays for diagnosing cancer, inflammatory conditions, immunological disorders, cardiovascular conditions, infectious diseases, and neurological conditions
Owner
- PARABILIS MEDICINES, INC., CAMBRIDGE, MA, US
- Fog Pharmaceuticals, Inc., Cambridge, MA, US
- Fog Pharmaceuticals, Inc., Cambridge, MA, US
- Fog Pharmaceuticals, Inc., Cambridge, MA, US
Prosecution history
- 19 Jan 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 19 Jan 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 19 Jan 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 06 Nov 2024 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 19 Dec 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 19 Dec 2023 — REGISTERED-PRINCIPAL REGISTER
- 17 Nov 2023 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 16 Nov 2023 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 31 Oct 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 30 Oct 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 30 Oct 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 23 Aug 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 23 Aug 2023 — NON-FINAL ACTION E-MAILED
- 23 Aug 2023 — SU - NON-FINAL ACTION - WRITTEN
- 10 Aug 2023 — STATEMENT OF USE PROCESSING COMPLETE